Volume 26, Issue 8 (11-2019)                   RJMS 2019, 26(8): 56-67 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bagheri-Mohammadi S, Noureddini M, Alani B. Stem cell therapies as potential candidates in Parkinson's disease treatment. RJMS 2019; 26 (8) :56-67
URL: http://rjms.iums.ac.ir/article-1-5664-en.html
PhD Student in Medical Physiology, Department of Physiology and Neurophysiology Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran , bagherimohammadi-sa@sbmu.ac.ir
Abstract:   (3770 Views)
Background: Treatment of Parkinson’s Disease (PD) has an important aim for the physicians, patients and families, and for the society. The experimental research by cell therapy for PD has commonly used stem cells as the donor source. Human Endometrial Derived Stem Cells (HEDSCs), a readily obtainable type of mesenchymal stem-like cell was used to generate Dopaminergic (DA) neurons. The aim of this study was to investigate the therapeutic effect of intranasal administration of endometrial stem cells in mouse model of PD.
Methods: In this investigation, for evaluation therapeutic efficacy of intranasal administration of HEDSCs in 6-OHDA induced mouse model of PD, 28 male mice weighting 25-30 gr were divided into 4 groups. On days 30, 60, 90, and 120 post stem cells administrated, the rotational behavior was measured. The animal received an intraperitoneal injection of apomorphine (0.5 mg/kg), and was placed in an opaque cylinder. Also, to evaluate differentiation of HEDSCs in to the neural cells in mice brain, immunohistochemistry staining by using human neural Nesti was performed.
Results: The result indicated that the intranasal administration of HEDSCs could decrease rotational behavioral compared with control group significantly post cell therapy in mouse model of PD. Besides, endometrial stem cells could differentiate into neural cells.
Full-Text [PDF 1338 kb]   (1344 Downloads)    
Type of Study: Research | Subject: Physiology

1. 1. Pakkenberg B, Møller A, Gundersen H, Dam AM, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry; 1991.54(1):30-3.
2. 2. Mohammadi R, Fallahmohammadi Z, Aghajani K. Pre-treatment effects of hydroalcoholic extraction of Eriobotrya japonica on GDNF levels in the brain stem of parkinsonian rats after 6 weeks of voluntary exercise. Razi J Med Sci; 2015.21(128):1-7.
3. 3. Mostafavian Z, Gohardehi F, Shakerian S, Nojomi M, Kiaee A, Gholamipour A, et al. Quality of life in patients with Parkinson's disease: Assessing with the Parkinson's Disease Questionnaire (PDQ-39). Razi J Med Sci; 2012.19(94):33-9.
4. 4. Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, et al. The association of incident dementia with mortality in PD. Neurology; 2002.59(11):1708-13.
5. 5. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature; 2006.441(7097):1094.
6. 6. Barker RA, Barrett J, Mason SL, Björklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol; 2013.12(1):84-91.
7. 7. John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, Raine CS, et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nature Med; 2002.8(10):1115.
8. 8. Kim C, Lee HC, Sung J-J. Amyotrophic lateral sclerosis-cell based therapy and novel therapeutic development. Experim neurobiol; 2014.23(3):207-14.
9. 9. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron; 2003.39(6):889-909.
10. 10. Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson's disease. BioMed Res Int; 2012.2012.
11. 11. Nam H, Lee KH, Nam D-H, Joo KM. Adult human neural stem cell therapeutics: Current developmental status and prospect. World J Stem Cells; 2015.7(1):126.
12. 12. Ikegame Y, Yamashita K, Nakashima S, Nomura Y, Yonezawa S, Asano Y, et al. Fate of graft cells: what should be clarified for development of mesenchymal stem cell therapy for ischemic stroke? Front Cell Neurosci; 2014.8:322.
13. 13. Kitada M, Dezawa M. Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinson’s Dis; 2012.2012.
14. 14. Sundberg M, Isacson O. Advances in stem-cell–generated transplantation therapy for Parkinson's disease. Expert Opin Biol Ther; 2014.14(4):437-53.
15. 15. Ghobadi F, Mehrabani D, Mehrabani G. Regenerative potential of endometrial stem cells: a mini review. World J Plastic Surg; 2015.4(1):3.
16. 16. Wolff EF, Mutlu L, Massasa EE, Elsworth JD, Eugene Redmond Jr D, Taylor HS. Endometrial stem cell transplantation in MPTP‐exposed primates: an alternative cell source for treatment of P arkinson's disease. J Cell Mol Med; 2015.19(1):249-56.
17. 17. Verdi J, Tan A, Shoae-Hassani A, Seifalian AM. Endometrial stem cells in regenerative medicine. J Biol Engin; 2014.8(1):20.
18. 18. Shoae‐Hassani A, Sharif S, Seifalian AM, Mortazavi‐Tabatabaei SA, Rezaie S, Verdi J. Endometrial stem cell differentiation into smooth
19. muscle cell: a novel approach for bladder tissue engineering in women. BJU Int; 2013.112(6):854-63.
20. 19. Noureddini M, Verdi J, Mortazavi‐Tabatabaei SA, Sharif S, Azimi A, Keyhanvar P, et al. Human endometrial stem cell neurogenesis in response to NGF and bFGF. Cell Biol Int; 2012.36(10):961-6.
21. 20. Kozłowska H, Jabłonka J, Janowski M, Jurga M, Kossut M, Domańska-Janik K. Transplantation of a novel human cord blood-derived neural-like stem cell line in a rat model of cortical infarct. Stem cells Develop; 2007.16(3):481-8.
22. 21. Yang B, Migliati E, Parsha K, Schaar K, Xi X, Aronowski J, et al. Intra-arterial delivery is not superior to intravenous delivery of autologous bone marrow mononuclear cells in acute ischemic stroke. Stroke; 2013.44(12):3463-72.
23. 22. Fransson M, Piras E, Wang H, Burman J, Duprez I, Harris RA, et al. Intranasal delivery of central nervous system‐retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis. Immunology; 2014.142(3):431-41.
24. 23. Danielyan L, Beer-Hammer S, Stolzing A, Schäfer R, Siegel G, Fabian C, et al. Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease. Cell transplantation. 2014;23(1_suppl):123-39.
25. 24. Vahidinia Z, Alipour N, Atlasi MA, Naderian H, Beyer C, Azami Tameh A. Gonadal steroids block the calpain-1-dependent intrinsic pathway of apoptosis in an experimental rat stroke model. Neurol Res; 2017.39(1):54-64.
26. 25. Lee S, Choi E, Cha MJ, Hwang KC. Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy. Oxid Med Cell Longev; 2015.2015.
27. 26. Wolff EF, Gao XB, Yao KV, Andrews ZB, Du H, Elsworth JD, et al. Endometrial stem cell transplantation restores dopamine production in a Parkinson’s disease model. J Cell Mol Med; 2011.15(4):747-55.
28. 27. Dhanda DS, Frey W, Leopold D, Kompella UB. Approaches for drug deposition in the human olfactory epithelium. Drug Deliv Technol;. 2005.5(4):64-72.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb